A meta-analysis by Conforti and colleagues involving 1672 advanced NSCLC patients found that anti-PD1 or anti-PD-L1 monotherapy was highly effective in men but not in women, even in patients expressing high PD-L1 levels [31]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.